CEL-SCI Corporation: CEL-SCI's Multikine Phase 3 Cancer Study Shows 43% Survival Extension
Presented at the 10th European Congress on Head Neck Oncology Six Different Efficacy Measures Demonstrate Benefits of Adding Multikine to Standard of Care for Patients Who Have Not Had New
United States Dennis Riedl Eyal Talor Geert Kersten Exchange Commission European Congress On Head Neck Oncology
Source: finanznachrichten.de